287 related articles for article (PubMed ID: 33308870)
1. Management of Advanced Penile Cancer.
Chahoud J; Kohli M; Spiess PE
Mayo Clin Proc; 2021 Mar; 96(3):720-732. PubMed ID: 33308870
[TBL] [Abstract][Full Text] [Related]
2. Emerging Systemic Therapies for the Management of Penile Cancer.
Gupta S; Sonpavde G
Urol Clin North Am; 2016 Nov; 43(4):481-491. PubMed ID: 27717434
[TBL] [Abstract][Full Text] [Related]
3. Immune landscape and immunotherapy for penile cancer.
Tang Y; Hu X; Wu K; Li X
Front Immunol; 2022; 13():1055235. PubMed ID: 36524123
[TBL] [Abstract][Full Text] [Related]
4. Contemporary management of patients with penile cancer and lymph node metastasis.
Leone A; Diorio GJ; Pettaway C; Master V; Spiess PE
Nat Rev Urol; 2017 Jun; 14(6):335-347. PubMed ID: 28401957
[TBL] [Abstract][Full Text] [Related]
5. Innovative systemic therapies for penile cancer.
Chahoud J; Pham R; Sonpavde G
Curr Opin Urol; 2022 Jan; 32(1):8-16. PubMed ID: 34738984
[TBL] [Abstract][Full Text] [Related]
6. Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy.
Pond GR; Di Lorenzo G; Necchi A; Eigl BJ; Kolinsky MP; Chacko RT; Dorff TB; Harshman LC; Milowsky MI; Lee RJ; Galsky MD; Federico P; Bolger G; DeShazo M; Mehta A; Goyal J; Sonpavde G
Urol Oncol; 2014 May; 32(4):501-8. PubMed ID: 24332646
[TBL] [Abstract][Full Text] [Related]
7. The role of Her-2 in penile squamous cell carcinoma progression and cisplatin chemoresistance and potential for antibody-drug conjugate-based therapy.
Tan X; Wang Y; Wu Z; Zhou Q; Tang Y; Liu Z; Yuan G; Luo S; Zou Y; Guo S; Han N; Yao K
Eur J Cancer; 2023 Nov; 194():113360. PubMed ID: 37862796
[TBL] [Abstract][Full Text] [Related]
8. Insights into the management of penile squamous cell carcinoma: from conventional approaches to emerging novel therapies.
Safa H; Mercinelli C; Spiess PE; Necchi A; Chahoud J
Expert Opin Pharmacother; 2024 Mar; 25(4):447-465. PubMed ID: 38549550
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.
Ali SM; Pal SK; Wang K; Palma NA; Sanford E; Bailey M; He J; Elvin JA; Chmielecki J; Squillace R; Dow E; Morosini D; Buell J; Yelensky R; Lipson D; Frampton GM; Howley P; Ross JS; Stephens PJ; Miller VA
Oncologist; 2016 Jan; 21(1):33-9. PubMed ID: 26670666
[TBL] [Abstract][Full Text] [Related]
10. [Penile cancer - a challenge for modern uro-oncology].
Protzel C; Hakenberg OW
Aktuelle Urol; 2013 Sep; 44(5):363-9. PubMed ID: 24043535
[TBL] [Abstract][Full Text] [Related]
11. EGFR mono-antibody salvage therapy for locally advanced and distant metastatic penile cancer: Clinical outcomes and genetic analysis.
Huang KB; Liu RY; Peng QH; Li ZS; Jiang LJ; Guo SJ; Zhou QH; Liu TY; Deng CZ; Yao K; Qin ZK; Liu ZW; Li YH; Han H; Zhou FJ
Urol Oncol; 2019 Jan; 37(1):71-77. PubMed ID: 30446465
[TBL] [Abstract][Full Text] [Related]
12. Treating advanced penile cancer: where do we stand in 2019?
Aydin AM; Cheriyan S; Spiess PE
Curr Opin Support Palliat Care; 2019 Sep; 13(3):249-254. PubMed ID: 31082941
[TBL] [Abstract][Full Text] [Related]
13. Preoperative plasma IGFBP2 is associated with nodal metastasis in patients with penile squamous cell carcinoma.
Hu X; Chen M; Liu W; Li Y; Fu J
Urol Oncol; 2019 Jul; 37(7):452-461. PubMed ID: 31053522
[TBL] [Abstract][Full Text] [Related]
14. Penile cancer.
Thomas A; Necchi A; Muneer A; Tobias-Machado M; Tran ATH; Van Rompuy AS; Spiess PE; Albersen M
Nat Rev Dis Primers; 2021 Feb; 7(1):11. PubMed ID: 33574340
[TBL] [Abstract][Full Text] [Related]
15. Second line salvage systemic therapy for advanced penile cancer.
Chahoud J; Tamil M; Necchi A
Urol Oncol; 2022 Jun; 40(6):229-234. PubMed ID: 32950396
[TBL] [Abstract][Full Text] [Related]
16. SPP1 is associated with adverse prognosis and predicts immunotherapy efficacy in penile cancer.
Zou Y; Tan X; Yuan G; Tang Y; Wang Y; Yang C; Luo S; Wu Z; Yao K
Hum Genomics; 2023 Dec; 17(1):116. PubMed ID: 38111044
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry Study.
Mollica V; Massari F; Maruzzo M; Bimbatti D; Claps M; Maiorano BA; Vitale MG; Iacovelli R; Ermacora P; Roviello G; Calabrò F; Caffo O; Vignani F; Grillone F; Pierantoni F; Di Napoli M; Mennitto A; Marchetti A; Mattana A; Cavo A; Bassanelli M; Formisano L; Prati V; Giudice GC; Buti S
Clin Genitourin Cancer; 2024 Jun; 22(3):102074. PubMed ID: 38616147
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus infection affects treatment outcomes and the immune microenvironment in patients with advanced penile squamous cell carcinoma receiving programmed cell death protein 1 inhibitor-based combination therapy.
Wei L; Li Z; Guo S; Ma H; Shi Y; An X; Huang K; Xiong L; Xue T; Zhang Z; Yao K; Luo J; Han H
Cancer; 2024 May; 130(9):1650-1662. PubMed ID: 38157276
[TBL] [Abstract][Full Text] [Related]
19. The case for nonsurgical therapy of nonmetastatic penile cancer.
Tward J
Nat Rev Urol; 2018 Sep; 15(9):574-584. PubMed ID: 29950592
[TBL] [Abstract][Full Text] [Related]
20. Current controversies and developments on the role of lymphadenectomy for penile cancer.
Azizi M; Chipollini J; Peyton CC; Cheriyan SK; Spiess PE
Urol Oncol; 2019 Mar; 37(3):201-208. PubMed ID: 30301700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
